186 related articles for article (PubMed ID: 36685836)
1. Identification of ubiquitination-related gene classification and a novel ubiquitination-related gene signature for patients with triple-negative breast cancer.
Zhao K; Zheng Y; Lu W; Chen B
Front Genet; 2022; 13():932027. PubMed ID: 36685836
[No Abstract] [Full Text] [Related]
2. Identification of a novel ubiquitination related gene signature for patients with breast cancer.
Zheng Y; Lu W; Chen B; Zhao K
Medicine (Baltimore); 2022 Sep; 101(37):e30598. PubMed ID: 36123926
[TBL] [Abstract][Full Text] [Related]
3. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
4. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.
Shen X; Zhong J; He J; Han J; Chen N
Front Immunol; 2022; 13():978092. PubMed ID: 36105819
[TBL] [Abstract][Full Text] [Related]
5. A novel fatty-acid metabolism-based classification for triple negative breast cancer.
Yang X; Tang W; He Y; An H; Wang J
Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837
[TBL] [Abstract][Full Text] [Related]
6. A ubiquitination-related risk model for predicting the prognosis and immunotherapy response of gastric adenocarcinoma patients.
Shao S; Sun Y; Zhao D; Tian Y; Yang Y; Luo N
PeerJ; 2024; 12():e16868. PubMed ID: 38313020
[TBL] [Abstract][Full Text] [Related]
7. A novel immune checkpoint-related gene signature for predicting overall survival and immune status in triple-negative breast cancer.
Liu J; Ling Y; Su N; Li Y; Tian S; Hou B; Luo S; Zhao L; Shi M
Transl Cancer Res; 2022 Jan; 11(1):181-192. PubMed ID: 35261895
[TBL] [Abstract][Full Text] [Related]
8. Identification of a Hypoxia-Related Molecular Classification and Hypoxic Tumor Microenvironment Signature for Predicting the Prognosis of Patients with Triple-Negative Breast Cancer.
Sun X; Luo H; Han C; Zhang Y; Yan C
Front Oncol; 2021; 11():700062. PubMed ID: 34490098
[TBL] [Abstract][Full Text] [Related]
9. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer.
Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM
Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558
[TBL] [Abstract][Full Text] [Related]
10. Novel molecular insights into pyroptosis in triple-negative breast cancer prognosis and immunotherapy.
Yu B; Luo J; Yang Y; Zhen K; Shen B
J Gene Med; 2024 Jan; 26(1):e3645. PubMed ID: 38041540
[TBL] [Abstract][Full Text] [Related]
11. An iron metabolism and immune related gene signature for the prediction of clinical outcome and molecular characteristics of triple-negative breast cancer.
Li XF; Fu WF; Zhang J; Song CG
BMC Cancer; 2022 Jun; 22(1):619. PubMed ID: 35668369
[TBL] [Abstract][Full Text] [Related]
12. Construction and Validation of a Prognostic Risk Model for Triple-Negative Breast Cancer Based on Autophagy-Related Genes.
Yan C; Liu Q; Jia R
Front Oncol; 2022; 12():829045. PubMed ID: 35186763
[TBL] [Abstract][Full Text] [Related]
13. A CTL/M2 macrophage-related four-gene signature predicting metastasis-free survival in triple-negative breast cancer treated with adjuvant radiotherapy.
Ye Y; Ma J; Zhang Q; Xiong K; Zhang Z; Chen C; Xiao H; Wang D
Breast Cancer Res Treat; 2021 Nov; 190(2):329-341. PubMed ID: 34482483
[TBL] [Abstract][Full Text] [Related]
14. The molecular subtypes of triple negative breast cancer were defined and a ligand-receptor pair score model was constructed by comprehensive analysis of ligand-receptor pairs.
Pan W; Song K; Zhang Y; Yang C; Zhang Y; Ji F; Zhang J; Shi J; Wang K
Front Immunol; 2022; 13():982486. PubMed ID: 36119101
[TBL] [Abstract][Full Text] [Related]
15. A pyroptosis-associated gene risk model for predicting the prognosis of triple-negative breast cancer.
Qiu P; Guo Q; Pan K; Chen J; Lin J
Front Oncol; 2022; 12():890242. PubMed ID: 36276158
[TBL] [Abstract][Full Text] [Related]
16. Establishment and validation of a ubiquitination-related gene signature associated with prognosis in pancreatic duct adenocarcinoma.
Guo Y; Wu Z; Cen K; Bai Y; Dai Y; Mai Y; Hong K; Qu L
Front Immunol; 2023; 14():1171811. PubMed ID: 37359528
[TBL] [Abstract][Full Text] [Related]
17. Identification of immune-related signature for the prognosis and benefit of immunotherapy in triple-negative breast cancer.
Sun X; Zhang T
Front Genet; 2022; 13():1067254. PubMed ID: 36452159
[No Abstract] [Full Text] [Related]
18. High Throughput Transcriptome Data Analysis and Computational Verification Reveal Immunotherapy Biomarkers of Compound Kushen Injection for Treating Triple-Negative Breast Cancer.
Liu X; Wu Y; Zhang Y; Bu D; Wu C; Lu S; Huang Z; Song Y; Zhao Y; Guo F; Ye P; Fu C; Shen L; Zhang J; Wang H; Duan X; Wu J
Front Oncol; 2021; 11():747300. PubMed ID: 34604090
[TBL] [Abstract][Full Text] [Related]
19. SENP3 promotes tumor progression and is a novel prognostic biomarker in triple-negative breast cancer.
Zhu Y; Zhang J; Yu L; Xu S; Chen L; Wu K; Kong L; Lin W; Xue J; Wang Q; Lin Y; Chen X
Front Oncol; 2022; 12():972969. PubMed ID: 36698419
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel glycolysis-related prognosis risk signature in triple-negative breast cancer.
Ruan Y; Tang Q; Qiao J; Wang J; Li H; Yue X; Sun Y; Wang P; Yang H; Liu Z
Front Oncol; 2023; 13():1171496. PubMed ID: 37274269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
